An interventional study of MILC application and Usual care in Breastfeeding, Exclusive, sponsored by Benten Technologies, Inc.. Withdrawn at 3 sites in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Benten Technologies, Inc. · Not applicable, Interventional, and Supportive care
Lapse in SBIR reauthorization and lack of funding
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Breast Feeding with a site in United States — 43 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.
Among the 251 studies in Breast Feeding with a site in United States, this one is the 189th largest by enrollment of the 202 interventional ones that give a count, is one of 16 that started in 2025, is one of 164 with no phase, and was the 222nd registered.
1,083 studies on the registry are indexed under Breast Feeding; 216 are open to participants now.
Browse Breast Feeding studies →43 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Women only
University of Illinois at Urbana-Champaign · Sites in United States
Ages 21–45 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
University of Colorado, Denver · Sites in United States
Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Breast Feeding studies recruiting now, 65 (52%) set no upper age limit and 58 (46%) stop at 75 or younger; 52 take children under 18; 75 take healthy volunteers.
This study: 18 Years to 44 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 6 · Phase 4 14
First in 2000; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 83 across the 202 interventional studies, 88 across the 49 observational. Of the 180 that completed or were terminated, 47 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 251 have an industry lead sponsor. The 10 most frequent:
Benten Technologies, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Benten Technologies, Inc. has 2 studies filed under Breast Feeding — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Feeding with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06107933Johns Hopkins Bloomberg School of Public HealthDevelopmental Impacts of Microplastics Exposure in Early Life | 2026-12-31 |
| NCT05441709Endeavor HealthFurthering Equity Through Infant Feeding EDucation and Support | 2026-12-31 |
| NCT03838536University of North Carolina, Chapel HillSynergistic Activity of Human Milk Nutrients and Infant Cognition | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 251 studies in Breast Feeding with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The innovative platform MILC is designed to provide an integrated and comprehensive professional and social support network with personalized breastfeeding (BF) education to target exclusive breastfeeding (EBF) and any BF behaviors in low-income Hispanic women. Formative research conducted for the development of MILC and results from pilot testing will help guide the completion of the development and testing of this prototype that specifically caters to Hispanic women. In the long term, MILC has the potential to increase the rates of EBF and any BF up to 12 months.
Breastfeeding (BF) is positively associated with health benefits for infants. It reduces an infant's risks for various conditions such as respiratory tract infections, non-specific gastroenteritis, diarrhea, asthma, and sudden infant death syndrome (SIDS).
Despite high breastfeeding (BF) initiation of approximately 80% among the Hispanic population in the United States (US), less than 25% of infants were exclusively breastfed (EBF) through 6 months, further perpetuating ethnic disparities in chronic diseases such as diabetes, obesity, and hypertension. Hispanic women are more likely to supplement feeding with formula, than non-Hispanic or African American (AA) mothers. Research has reported that barriers such as insufficient BF education, lack of BF technical support (i.e. latching issues, sore nipples), returning to work, easy access to free or discounted formula milk from Women Infants and Children (WIC), lack of social support, perceived inconvenience, cultural belief that both formula and breastmilk (los-dos) is best for the babies, perception that the infant is not satiated, and embarrassment associated with breastfeeding result in premature weaning off BF among low-income Hispanic mothers. Therefore, increasing the duration of EBF and continuous BF among low-income Hispanic women would require an innovative and comprehensive approach that addresses the diverse range of barriers listed above.
The investigators hypothesize that MILC will show significantly higher percentages of BF mothers in the intervention group at each time (1 month, 3 months, and 6 months) point compared with the control group. In the short term, MILC will be shown to be usable and acceptable by Hispanic BF mothers to receive BF support, education, and guidance from primary care providers (PCP) and certified lactation consultants/international board certified lactation consultants (CLC/IBCLC). In the long term, the impact of MILC will increase the rates of EBF for up to 6 months along with increasing rates of any BF up to 12 months.
Inclusion Criteria for focus groups:
Inclusion Criteria for Randomized Control Trial (RCT):
Exclusion Criteria for focus groups and Randomized Control Trial (RCT):
Women who report the following conditions also will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible Hispanic participants in their third trimester will be recruited for the study. The intervention group will receive standard WIC services plus the MILC application.
Behavioral: MILC application
Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program.
Behavioral: Usual care
Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and "any BF"). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect.
Exclusive breastfeeding
Investigators will assess if participants are breastfeeding exclusively (EBF)through monthly self-reported information. Investigators will record information on EBF at 1 month, 3 months and 6 months among women in the intervention arm.
Time frame: 1 month, 3 months and 6 months
Any breastfeeding rate(EBF)
Investigators will assess if participants are continuous breastfeeding through monthly breastfeeding videos uploaded in the system. Investigators will report information on any breastfeeding at 1 month, 3 months and 6 months.
Time frame: 1 month, 3 months and 6 months
Infant weight (Medical outcomes)
Infant's weight using medical report collected at 1 month, 3 month and 6 months
Time frame: Baseline, 1 month, 3 months and 6 months
Emergency department visit (Medical outcomes)
Number of emergency department visited for infant will be collected at 1 month, 3 month and 6 months
Time frame: Baseline, 1 month, 3 months and 6 months
Latching
It will be assessed using LATCH breastfeeding assessment scale. LATCH stands for latch, audible swallowing, type of nipple, comfort and hold. Each component is scored from 0-2. A LATCH score of 0-3 is regarded as poor, 4-7 as moderate, and 8-10 as good.
Time frame: Baseline, 1 month, 3 months and 6 months
BF history & attitudes questionnaire
New survey based on constructs that potentially moderate BF
Time frame: Baseline, 1 month, 3 months and 6 months
Self-Efficacy Scale
It will be assessed using the BF Self-Efficacy Scale Short Form (BSES-SF). The BSES-SF is a 14-item self-administered instrument derived from the original 33-item BSES that measures breastfeeding confidence. Total scores range from 14 to 70, with higher scores reflecting more significant levels of breastfeeding self-efficacy.
Time frame: Baseline, 1 month, 3 months and 6 months
Iowa Infant Feeding Attitude
It will be collected using the Iowa infant feeding attitudes scale (IIFAS). The scale is composed of 17 items for assessing attitude towards BF. The total IIFAS score can range from 17 to 85 with higher scores reflecting positive attitude towards breastfeeding
Time frame: Baseline, 1 month, 3 months and 6 months
Acculturation
It will be assessed by using the Acculturation Rating Scale for Mexican Americans II. The scale contains 48 items to which participants respond on a 5-point Likert scale ranging from "Not at all" to "Extremely often or almost always," with higher scores indicating greater cultural orientation.
Time frame: Baseline, 1 month, 3 months and 6 months
Postnatal depression
It will be assessed using Edinburgh Postnatal depression Scale (EPDS). The EPDS has a maximum score of 30; a score of 10 or more may indicate possible depression of varying severity.
Time frame: Baseline, 1 month, 3 months and 6 months
Usability
System Usability Scale (SUS)survey will be used to assess usability of the MILC app. A SUS score above 68 would be considered above average and anything below 68 is below average.
Time frame: Month 6 postpartum
Acceptance and Adoption
Technology Acceptance Model (TAM) will be used to assess acceptance of MILC app
Time frame: Month 6 postpartum
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jun 2025, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Aug 2024 → Jun 2025 and primary completion Feb 2025 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Lapse in SBIR reauthorization and lack of funding
Lapse in SBIR reauthorization and lack of funding
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Benten Technologies, Inc.